A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Pulmonx Corp stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 1,114,297 shares of LUNG stock, worth $7.06 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,114,297
Previous 1,059,018 5.22%
Holding current value
$7.06 Million
Previous $6.71 Million 37.59%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$5.59 - $8.58 $309,009 - $474,293
55,279 Added 5.22%
1,114,297 $9.24 Million
Q2 2024

Jul 29, 2024

BUY
$5.77 - $9.82 $401,563 - $683,422
69,595 Added 7.03%
1,059,018 $6.71 Million
Q1 2024

May 08, 2024

BUY
$8.71 - $14.65 $521,162 - $876,582
59,835 Added 6.44%
989,423 $9.17 Million
Q4 2023

Feb 09, 2024

BUY
$7.89 - $13.14 $252,977 - $421,307
32,063 Added 3.57%
929,588 $11.9 Million
Q3 2023

Nov 13, 2023

SELL
$9.88 - $14.0 $101,437 - $143,738
-10,267 Reduced 1.13%
897,525 $9.27 Million
Q2 2023

Aug 08, 2023

SELL
$10.78 - $13.65 $746,396 - $945,112
-69,239 Reduced 7.09%
907,792 $11.9 Million
Q1 2023

May 08, 2023

BUY
$7.49 - $12.54 $57,807 - $96,783
7,718 Added 0.8%
977,031 $10.9 Million
Q4 2022

Feb 09, 2023

BUY
$4.92 - $17.35 $230,147 - $811,598
46,778 Added 5.07%
969,313 $8.17 Million
Q3 2022

Nov 10, 2022

SELL
$15.35 - $23.99 $12,203 - $19,072
-795 Reduced 0.09%
922,535 $15.4 Million
Q2 2022

Aug 04, 2022

BUY
$14.0 - $27.95 $1.49 Million - $2.98 Million
106,654 Added 13.06%
923,330 $13.6 Million
Q1 2022

May 12, 2022

BUY
$21.13 - $35.65 $5.49 Million - $9.26 Million
259,844 Added 46.66%
816,676 $20.3 Million
Q4 2021

Feb 09, 2022

BUY
$29.72 - $45.1 $16.5 Million - $25.1 Million
556,832 New
556,832 $17.9 Million

Others Institutions Holding LUNG

About Pulmonx Corp


  • Ticker LUNG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 37,268,400
  • Market Cap $236M
  • Description
  • Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...
More about LUNG
Track This Portfolio

Track Bnp Paribas Asset Management Holding S.A. Portfolio

Follow Bnp Paribas Asset Management Holding S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bnp Paribas Asset Management Holding S.A., based on Form 13F filings with the SEC.

News

Stay updated on Bnp Paribas Asset Management Holding S.A. with notifications on news.